Pharming Group N.V. (AMS:PHARM)
Netherlands · Delayed Price · Currency is EUR | Market Cap | 964.00M +74.2% |
| Revenue (ttm) | 320.35M +26.6% |
| Net Income | 2.43M |
| EPS | 0.00 |
| Shares Out | 685.15M |
| PE Ratio | 397.00 |
| Forward PE | 53.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,869,329 |
| Average Volume | 9,814,929 |
| Open | 1.400 |
| Previous Close | 1.407 |
| Day's Range | 1.355 - 1.402 |
| 52-Week Range | 0.656 - 1.818 |
| Beta | 0.16 |
| RSI | 50.45 |
| Earnings Date | Mar 12, 2026 |
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev... [Read more]
News
Pharming Group's Leniolisib Gets Japan Approval To Treat APDS Patients Aged 4 Years And Older
(RTTNews) - Dutch biopharmaceutical company Pharming Group N.V. (PHAR, PHGUF,, PHARM.AS) announced Tuesday that Japan's Ministry of Health, Labour and Welfare or MHLW has approved Joenja (leniolisib),...
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
Leiden, the Netherlands, March 24, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced that Japan's Ministry of Health, Labour and Welfare ...
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Pharming Group (PHGUF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Pharming Group (PHGUF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges
Q4 2025 Pharming Group NV Earnings Call Transcript
Q4 2025 Pharming Group NV Earnings Call Transcript
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ: MCRB) is likely to report quarterly loss at $1.92 per share on revenue of $5.88 million. • Ollie's Bargain Outlet (NASDAQ: OLLI) is ...
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
Pharming Group (XAMS:PHARM) Q4 2025 Earnings Report Preview: What to Expect
Pharming Group (XAMS:PHARM) Q4 2025 Earnings Report Preview: What to Expect
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advise...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR).
Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12
Pharming to report 4th quarter full year 2025 financial results & provide a business update on March 12, 2026 & host conference call 13:30 CET/08:30 EDT.
Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Pharming to attend and present at Oppenheimer 36th Annual Healthcare Life Sciences Conference. CEO & CMO to present on February 25 at 12:40pm ET/18:40 CET.
Pharming Group: Crossing From Speculation To Profitability
Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company. PHAR delivered $376M in FY2025 revenue, up 27% YoY, surpassing guidance, an...
Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript
Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS
Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) t...
Pharming Group reports preliminary 2025 revenues and announces Investor Day
Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full ye...
Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit
Pharming to participate in Oppenheimer Movers in Rare Disease Summit on Dec 11 in NYC. Chief Medical Officer Anurag Relan in fireside chat at 1:50 PM ET.
Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript
Pharming Group N.V. ( PHAR) Q3 2025 Earnings Call November 6, 2025 7:30 AM EST Company Participants Fabrice Chouraqui - CEO & Executive Director Stephen Toor - Chief Commercial Officer & GM Americas ...
Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Health...
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
Pharming to report third quarter 2025 financial results and provide a business update on November 6, 2025, and host conference call at 13:30 CET/07:30 ET.
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Pharming announces 12 abstracts have been accepted for presentation at 2025 ACAAI Annual Scientific meeting being held in Orlando, Florida on November 6-10
Pharming Group provides update on previously announced G&A expense reduction plan
Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to acc...
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Decision based o...
Pharming Group promoted to the Euronext AMX® index
Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small ...
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th A...